Brentuximab Vedotin 50mg/Vial Injection — CD30-directed antibody-drug conjugate
| Composition | Brentuximab Vedotin 50 mg |
|---|---|
| Manufacturer | Seagen Inc. (Pfizer) |
| Country | United States |
| Pack size | 1 single-dose vial (50 mg/vial) |
| Storage | Refrigerate at 2°C to 8°C in original carton, protect from light |
Supplied only against a valid prescription from a registered medical practitioner.
Sourced from authorised channels
Temperature-controlled packing
Hospitals, clinics, pharmacies
Delhi drug licence holder
Adcetris® (Brentuximab Vedotin) — CD30-Directed Antibody-Drug Conjugate: A Sourcing Guide for Hospitals and Oncology Centres
Adcetris® (brentuximab vedotin) is a CD30-directed antibody and microtubule inhibitor conjugate. According to its approved US prescribing information, it is indicated for certain patients with classical Hodgkin lymphoma (cHL), systemic anaplastic large cell lymphoma (sALCL), other CD30-expressing peripheral T-cell lymphomas, primary cutaneous ALCL or CD30-expressing mycosis fungoides, and, in combination with lenalidomide and a rituximab product, relapsed or refractory large B-cell lymphoma (LBCL) in defined patient groups. The decision to prescribe Adcetris, including patient selection, combination partners, schedule and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Adcetris (brentuximab vedotin) 50 mg vials to hospitals, oncology centres and pharmacies across India. Hospital buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the cancer medicines category. Supply is in bulk/wholesale quantities only.
Adcetris is an antibody-drug conjugate (ADC) made of three components, as described in the prescribing information: a chimeric IgG1 antibody directed at CD30, the microtubule-disrupting agent monomethyl auristatin E (MMAE), and a protease-cleavable linker that joins them.
How it works, according to the label: CD30 is a protein found on the surface of cells in several lymphomas. The label describes the ADC binding to CD30-expressing cells, being taken into the cell, and releasing MMAE, which disrupts the microtubule network and leads to cell-cycle arrest and cell death.
The current US prescribing information (DailyMed, revised 2025) lists the following. Indications in India and other countries may differ and are defined by each country’s regulator.
The studies below are summarised as published; they are cited for information about the evidence behind the label and are not a recommendation for any patient.
| Presentation | Strength | Administration |
|---|---|---|
| Lyophilised powder in a single-dose vial, individually boxed | 50 mg per vial | Intravenous infusion after reconstitution and dilution (per prescribing information) |
The label states that, after reconstitution with 10.5 mL of Sterile Water for Injection, the concentration is 5 mg/mL. The label also lists weight-based dosing schedules that differ by indication. These must be determined and followed exactly as directed by the treating physician and the approved prescribing information.
This page is written for hospital pharmacists, oncology and haematology department buyers, and pharmacies that source specialty oncology products. Adcetris is administered in a clinical setting under the supervision of an oncologist or haematologist, as described in the prescribing information.
The prescribing information reports, for monotherapy in adults, that the most common adverse reactions (20% or more) were peripheral neuropathy, fatigue, upper respiratory tract infection, musculoskeletal pain, nausea, diarrhoea, pyrexia, rash and cough. The label carries a boxed warning for progressive multifocal leukoencephalopathy (PML), a JC virus infection that can be fatal. Other warnings listed include infusion reactions and anaphylaxis, hematologic toxicities, serious infections, tumor lysis syndrome, hepatotoxicity, pulmonary toxicity, serious dermatologic reactions, gastrointestinal complications and hyperglycemia. This list is not complete; the full prescribing information governs.
All use should follow the approved prescribing information and the instructions of the treating physician.
Per the label, store vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Hospitals should follow their own hazardous-drug handling policies.
Adcetris was developed by Seagen Inc., now part of Pfizer. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Adcetris through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.
Is Adcetris available in India?
A.K. Pharma supplies Adcetris (brentuximab vedotin) 50 mg vials to hospitals and pharmacies in India. Contact us for current availability.
What does Adcetris contain?
Brentuximab vedotin, a CD30-directed antibody-drug conjugate, supplied as 50 mg lyophilised powder in a single-dose vial.
Can I order a single vial?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.
How should Adcetris be stored?
The label states 2°C to 8°C in the original carton, protected from light.
Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.
How do I request a quote?
Call or WhatsApp us, or use the contact details below.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.
